MK-8558

Drug Merck Sharp & Dohme Corporation
Total Payments
$1.8M
Transactions
44
Doctors
0
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2020 $1.1M 26 0
2019 $719,482 18 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $1.8M 44 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A Study of MK-8558 Drug-Drug Interaction with MK-8591 and MK-8558 Once Daily Pharmacokinetics Merck Sharp & Dohme Corporation $844,600 0
An Open-Label Clinical Trial to Evaluate the Pharmacokinetics and Relative Bioavailability of Three Formulations of MK-8558 in Healthy Adult Participants Merck Sharp & Dohme Corporation $495,900 0
An Open-Label Clinical Trial to Evaluate the Pharmacokinetics and RelativeBioavailability of Three Formulations of MK-8558 in Healthy Adult Participants Merck Sharp & Dohme Corporation $271,638 0
A Trial to Assess the Effects of Multiple, Once Weekly Oral Doses of MK-8558 on the Single-Dose Pharmacokinetics of a Combination Oral Contraceptive Levonorgestrel and Ethinyl Estradiol in Healthy Adult Female Participants Merck Sharp & Dohme Corporation $134,949 0
A Trial to Assess the Effects of Multiple, Once Weekly Oral Doses of MK-8558 on the Single-Dose Pharmacokinetics of a Combination Oral ContraceptiveLevonorgestrel and Ethinyl Estradiol in Healthy Adult Female Participants Merck Sharp & Dohme Corporation $90,922 0

Top Doctors Receiving Payments for MK-8558

Doctor Specialty Location Total Records
Unknown Lincoln, NE $1.8M 44

About MK-8558

MK-8558 is a drug associated with $1.8M in payments to 0 healthcare providers, recorded across 44 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.

Payment data is available from 2019 to 2020. In 2020, $1.1M was paid across 26 transactions to 0 doctors.

The most common payment nature for MK-8558 is "Unspecified" ($1.8M, 100.0% of total).

MK-8558 is associated with 5 research studies, including "A Study of MK-8558 Drug-Drug Interaction with MK-8591 and MK-8558 Once Daily Pharmacokinetics" ($844,600).